Abstract
The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.
MeSH terms
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Asian People*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / ethnology*
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Lomustine / administration & dosage
-
Male
-
Oligodendroglioma / drug therapy*
-
Oligodendroglioma / ethnology*
-
Procarbazine / administration & dosage
-
Survival Analysis
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Phytogenic
-
Procarbazine
-
Vincristine
-
Lomustine